Teva Pharmaceutical Industries Limited American Depositary Shar — Cash Flow (NYSE:TEVA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends Documents

Quarterly Annual

Cash from operating activities 1.22 B798 M1.59 B1.37 B1.25 B1.65 B 1.9 B Cash from investing activities 863 M1.52 B656 M968 M792 M737 M 38 M Cash from financing activities -1.89 B-2.17 B-1.49 B-1.91 B-1.79 B-2.15 B -401 M Free cash flow 1.22 B798 M1.59 B842 M749 M1.15 B 1.35 B

News

BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid - Teva Pharmaceutical Indus (NY

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer - TipRanks.com

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?